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Abstract
Background: We sought to quantify plasma high sensitivity cardiac troponin (hs-cTnT) levels, their determinants, and their
associations with left ventricular (LV) myocardial deformation in adult survivors of childhood acute leukaemias.
Methods and Results: One hundred adult survivors (57 males) of childhood acute leukaemias, aged 24.164.2 years, and 42
age-matched controls (26 males) were studied. Plasma cTnT was determined using a highly sensitive assay. Genotyping of
NAD(P)H oxidase and multidrug resistance protein polymorphisms was performed. Left ventricular function was assessed by
conventional, three-dimensional, and speckle tracking echocardiography. The medians (interquartile range) of hs-cTnT in
male and female survivors were 4.9 (4.2 to 7.2) ng/L and 1.0 (1.0 to 3.5) ng/L, respectively. Nineteen survivors (13 males, 6
females) (19%) had elevated hs-cTnT (.95th centile of controls). Compared to those without elevated hs-TnT levels, these
subjects had received larger cumulative anthracycline dose and were more likely to have leukaemic relapse, stem cell
transplant, and cardiac irradiation. Their LV systolic and early diastolic myocardial velocities, isovolumic acceleration, and
systolic longitudinal strain rate were significantly lower. Survivors having CT/TT at CYBA rs4673 had higher hs-cTnT levels
than those with CC genotype. Functionally, increased hs-cTnT levels were associated with worse LV longitudinal systolic
strain and systolic and diastolic strain rates.
Conclusions: Increased hs-cTnT levels occur in a significant proportion of adult survivors of childhood acute leukaemias and
are associated with larger cumulative anthracycline dose received, history of leukaemic relapse, stem cell transplant, and
cardiac irradiation, genetic variants in free radical metabolism, and worse LV myocardial deformation.
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Introduction
Survival of children with haematological malignancies has
increased significantly with improved medical care and incorpo-
ration of anthracyclines into chemotherapy protocols [1]. With the
population of adult survivors growing, recent long term follow-up
series of childhood cancer survivors have further reaffirmed
cardiovascular disorders as important causes of late morbidity and
mortality [2,3]. Identification of markers of early myocardial
damage would facilitate stratification of patients into groups at
varying risk of cardiac injury, which has implications on long term
management. This is especially relevant as predisposition to
anthracycline-induced cardiac damage, genetic and otherwise [4–
6], varies among patients.
Damage to cardiomyocytes increases the circulating level of
cardiac troponin T (cTnT), which provides the basis for using
plasma or serum cTnT as a cardiac biomarker for diagnosing
acute coronary syndrome [7,8]. Intriguingly, circulating cTnT is
detectable using standard assays in a small subset of general
population [9,10]. In these subjects who do not have overt
cardiovascular disease, detectable cardiac troponins have been
associated with increased risk of death and adverse cardiovascular
risk profile and outcomes [9,10]. Detectable circulating cTnT,
albeit at a low level, may hence reflect subclinical myocardial
injury [7–11]. Furthermore, these reported associations suggest
that cTnT may be useful for detection of subclinical cardiovascular
disease in individuals at increased cardiovascular risk, although the
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relative low sensitivity of standard assays has limited the usefulness
of this potential application. New generation of highly sensitive
assay has enabled the measurement of very low circulating levels of
cTnT at approximately 10 fold lower than those detectable with
conventional assays [12–14]. In the general population, cTnT
level as quantified using the highly sensitive assay (hs-cTnT) has
been associated with cardiovascular risk factors and structural
alteration of the left ventricle, and shown to predict cardiovascular
risk and subsequent risk for all-cause mortality [12,13]. In patients
with chronic heart failure, changes in hs-cTnT concentrations
over time have also been shown to predict future cardiovascular
events [15].
In the present study, we sought to quantify plasma hs-cTnT
levels and determine factors associated with elevated hs-cTnT
levels in adult survivors of childhood leukaemias. We further
explored associations between plasma hs-cTnT levels and indices
of left ventricular (LV) function and myocardial deformation in
our survivors who did not have overt cardiac failure.
Methods
Ethics Statement
All subjects gave written informed consent to participate in this
study approved by the Institutional Review Board of The
University of Hong Kong/Hospital Authority West Cluster, Hong
Kong.
Subjects
One hundred anthracycline-treated adult survivors of childhood
leukaemias were recruited territory-wide from five public hospitals
in Hong Kong. These five hospitals treated nearly all childhood
cancers in Hong Kong. Inclusion criteria included i) survivors aged
18 to 35 years old, ii) history of acute leukaemia diagnosed before
18 years old, and iii) completion of cancer directed therapy for at
least 5 years. Exclusion criteria included i) history of congenital
heart disease, ii) syndromal disorders associated with congenital
heart disease, and iii) hypothyroidism not on replacement therapy.
Data collection from the case notes included the following:
diagnosis, age at diagnosis, date of completion of chemotherapy,
cumulative anthracycline dose, history of relapse, history of
cardiac irradiation, whether stem cell transplant has been
performed, major organ dysfunction, and current cardiac medi-
cations. Forty-two adult healthy subjects, including volunteer staff
members, their healthy friends and relatives, and healthy siblings
of survivors, were recruited as controls.
The body weight and height were measured and the body mass
index and body surface area were calculated accordingly. All
subjects rest for at least 15 minutes before echocardiographic
assessments, followed immediately by blood taking for assay of hs-
cTnT and genotyping as described below.
Echocardiographic Assessment
All echocardiographic assessments were performed using the
Vivid 7 ultrasound machine (GE Medical System, Horten,
Norway). The digital acquisitions were analyzed offline using the
EchoPAC software (GE Medical System, Horten, Norway). The
average value of the echocardiographic indices from three cardiac
cycles was calculated. All of the echocardiographic acquisitions
and analyses were performed by one single investigator (Wei Yu).
Parasternal short-axis view at mid-LV level was performed to
derive the following M-mode measurements: LV end-systolic and
end-diastolic dimensions, and thickness of interventricular septum
and posterior LV wall. The fractional shortening and the mass of
the left ventricle were calculated according to standard formulae.
Transmitral pulsed-wave Doppler examination was performed to
obtain the early (E) and late (A) inflow velocities and E
deceleration time. Tissue Doppler imaging was done with the
sample volume positioned at basal LV free wall-mitral annular
junction to obtain the peak systolic (s), and early (e) and late (a)
diastolic myocardial tissue velocities, e/a ratio, and LV free wall
myocardial acceleration during isovolumic contraction (IVA), the
latter being a relative load-independent index of LV contractile
function [16].
Speckle tracking echocardiography was used to assess global LV
longitudinal, radial, and circumferential strain and strain rate (SR)
as reported previously [17]. Briefly, the four-chamber apical plane
was acquired for assessment of LV longitudinal strain and strain
rate, while the short-axis plane at the papillary muscle level was
acquired for assessment of LV radial and circumferential strain
and strain rate. Additionally, three-dimensional echocardiography
was performed using the matrix ultrasound probe for derivation of
LV systolic and diastolic volumes and ejection fraction as
previously described [17].
Blood Investigations
Venous blood was collected using EDTA tubes for DNA
extraction and plasma samples were stored at 280uC until assay.
Plasma cTnT was measured using a highly sensitive assay (Elecsys-
2010 Troponin T hs, Roche Diagnostics), which has a lower
detection limit of 3 ng/L. Genotyping for polymorphism of
NAD(P)H oxidase (CYBA rs4673, RAC2 rs13058338, NCF4
rs1883112) and multidrug resistance protein (MRP1 rs45511401,
MRP2 rs17222723, MRP2 rs8187710), reported previously to be
associated with acute or chronic anthracycline-induced cardiotox-
icity [5] was performed. All allelic discrimination was performed
by ABI 7900HT Real-Time PCR system using pre-developed
TaqMan SNP genotyping assay (Applied Biosystems, Foster City,
CA USA), except for MRP1 rs45511401. MRP1 rs45511401
genotyping was performed by PCR-direct sequencing. Briefly,
PCR fragments were amplified and followed by sequencing with
ABI 37306l DNA Analyzer. Genotypes were determined by
homology analysis using BLAST (http://blast.ncbi.nlm.nih.gov/
Blast.cgi).
Statistical Analysis
Data are presented as mean6SD unless otherwise stated. Left
ventricular dimensions and volumes were indexed by body surface
area. Demographic variables and echocardiographic parameters
of survivors and controls were compared using Student’s t test and
Fisher’s exact test where appropriate. Comparison of plasma hs-
cTnT levels between survivors and controls, which had a non-
parametric distribution, was performed using Mann-Whitney U
test. The 95th percentiles of hs-cTnT in male and female healthy
controls were determined by non-parametric estimation. Male and
female survivors were then stratified into two groups based on the
respective cutoffs: group I with increased hs-cTnT levels .95th
centile and group II with hs-cTnT levels#95th centile. Differences
in variables between the two survivor subgroups were compared
using Student’s t test and Fisher’s exact test where appropriate. A
value of 1 ng/L was assigned for hs-cTnT levels below the limit of
detection (,3 ng/L), which would give a value of 0 after
logarithmic transformation. Logarithmic transformation of hs-
cTnT levels was performed to normalize the distribution of hs-
cTnT levels for correlation analyses. Within the survivor group,
correlations between natural log-transformed hs-cTnT levels and
indices of myocardial deformation and cumulative anthracycline
dose were determined by Pearson correlation analysis. Stepwise
multiple linear regression analysis was performed to identify
hs-cTnT in Survivors of Childhood Leukaemias
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significant determinants of natural log-transformed hs-cTnT level
in survivors. Genotypic and allelic frequencies were compared
between survivors and controls using Fisher’s exact test. A p value
,0.05 was considered statistically significant. All statistical
analyses were performed using IBM SPSS Statistics Version 19
(U.S.A).
Results
Subjects
The 100 survivors (57 males), aged 24.164.2 years, were
studied at 15.365.8 years after completion of cancer treatment.
Their age at diagnosis was 8.065.0 years. All had received
anthracycline as part of the chemotherapeutic regimen for the
treatment of acute lymphoblastic (n = 88) or myeloid (n = 12)
leukaemia. The mean cumulative anthracycline dose was
218698 mg/m2 (median 220, range 10 to 541 mg/m2). Of the
100 survivors, 23 had leukaemic relapse and 15 had undergone
stem cell transplant. Thirteen survivors, 12 of whom had stem cell
transplant and 1 had central nervous system leukaemia, had
received irradiation involving the heart. All of the survivors were
free from cardiac symptoms. One survivor received amlodipine for
systemic hypertension. Associated medical problems included
hypogonadism in 11, growth hormone deficiency in 1, hypo-
adrenalism in 1, hypothyroidism with replacement therapy in 1,
and development of parotid acinic cell carcinoma in 1. The 42
controls (26 males) were aged 25.464.1 years. While the age
(p = 0.10) and genders (p = 0.82) were similar between survivors
and controls, the survivors had significantly lower body weight
(p = 0.046), height (p,0.001), and body surface area (p= 0.006)
(Table 1).
Echocardiographic Parameters
Table 1 summarizes the echocardiographic findings in survivors
and controls. Compared with controls, survivors had slightly
lower, albeit statistically significant, LV shortening fraction
(p,0.001) and ejection fraction (p = 0.042), but similar Doppler
indices of LV systolic and diastolic function (all p.0.05). For
speckle tracking parameters, survivors had significantly lower
global LV longitudinal systolic strain (p = 0.049), circumferential
systolic strain (p = 0.001) and systolic (p = 0.027) and diastolic
(p = 0.049) strain rates, and radial systolic strain (p,0.001) and
systolic strain rate (p = 0.003) than controls.
Prevalence and Levels of Detectable hs-cTnT
For males, the prevalence of detectable plasma hs-cTnT in
survivors was 91.2% (95% CI, 81.1 to 96.2%) versus 84.6% (95%
CI, 66.5 to 93.9%) in controls (p = 0.45). For females, the
prevalence of detectable plasma hs-cTnT was 34.9% (95% CI,
22.4 to 49.8%) in survivors versus 31.3% (95% confidence
interval, 14.2 to 55.6%) in controls (p = 1.0). The distribution of
plasma hs-cTnT levels in survivors and controls is shown in
figure 1. The 95th percentile of plasma hs-cTnT level in healthy
controls as defined by nonparametric estimate was 7.91 ng/L in
males and 3.95 ng/L in females. Based on these cutoff values, a
total of 19 (13 males and 6 females) survivors were found to have
elevated plasma hs-cTnT levels, accounting for an overall
prevalence of 19.0% (95% CI, 12.5 to 27.8%).
Plasma hs-cTnT Levels and Clinical Variables
Comparisons of clinical variables by univariate analyses
between survivors with elevated hs-cTnT levels (group I) and
those without (group II) are summarized in Table 2. The two
groups shared similar demographic characteristics and types of
leukaemias (all p.0.05). However, the cumulative anthracycline
dose received by group I survivors was significantly higher
(p,0.001). More survivors in group I than in group II had
leukaemic relapse (p = 0.037), undergone stem cell transplant
Table 1. Comparisons of demographic and
echocardiographic findings between survivors and control
subjects.
Patients Controls p
(n =100) (n=42)
Demographics
Age (years) 24.164.2 25.464.1 0.10
Sex (M:F) 57:43 26:16 0.82
Weight (kg) 59.7612.1 64.1611.3 0.046*
Height (cm) 164.568.8 170.167.6 ,0.001*
Body surface area (m2) 1.660.2 1.760.2 0.006*
M-mode echocardiographic indices
Indexed LVEDd (mm) 29.763.6 30.463.0 0.31
Indexed LVESd (mm) 20.562.6 20.062.2 0.30
FS (%) 31.163.8 33.963.6 ,0.001*
Indexed LV mass (g/m2) 66.9616.9 69.3618.6 0.45
3D echocardiographic indices
LV end-systolic volume (ml/m2) 32.769.2 27.966.8 0.003*
LV end- diastolic volume (ml/m2) 70.1616.7 63.7613.2 0.032*
LV EF (%) 53.267.2 56.067.4 0.042*
Doppler indices
E (cm/s) 88.0617.1 84.3615.3 0.24
A (cm/s) 48.7612.6 45.5611.4 0.18
E/A ratio 1.960.6 2.060.5 0.82
E deceleration time (ms) 172.7634.6 163.4632.3 0.15
s (cm/s) 8.261.9 8.461.9 0.66
e (cm/s) 212.062.0 211.862.4 0.62
a (cm/s) 25.161.8 24.861.6 0.18
e/a 2.761.1 2.761.2 0.97
IVA (m/s2) 1.1960.49 1.2760.63 0.42
Deformation indices
Longitudinal strain (%) 216.063.1 17.163.2 0.049*
Longitudinal SRs(/s) 20.9360.18 20.9460.20 0.68
Longitudinal SRd(/s) 1.2860.32 1.3460.32 0.30
Circumferential strain (%) 214.363.5 216.664.7 0.001*
Circumferential SRs(/s) 20.9460.24 21.0660.33 0.027*
Circumferential SRd(/s) 1.1260.39 1.2760.45 0.049*
Radial strain (%) 32.9610.9 42.3612.5 ,0.001*
Radial SRs(/s) 1.9060.49 2.1460.57 0.003*
Radial SRd(/s) 21.8860.67 21.9960.67 0.36
Abbreviations: A, peak mitral inflow velocity at late diastole; a, mitral annular
late diastolic myocardial tissue velocity; E, peak mitral inflow velocity at early
diastole; e, mitral annual early diastolic myocardial tissue velocity; EF, ejection
fraction; FS, fractional shortening; IVA, isovolumic acceleration; LV, left
ventricular; LVEDd, left ventricular end diastolic dimension; LVESd, left
ventricular end systolic dimension; SRd, early diastolic strain rate; SRs, systolic
strain rate.
*statistically significant.
doi:10.1371/journal.pone.0077063.t001
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(p = 0.036), and received irradiation involving the heart
(p = 0.016).
The plasma hs-cTnT levels were significantly greater in
survivors who had irradiation involving the heart (median
5.23 ng/L vs 3.90 ng/L, p = 0.046), and also tended to be higher
in those with stem cell transplant (median 4.89 ng/L vs 3.88 ng/
L, p= 0.06) and leukaemic relapse (median 4.55 ng/L vs 3.65 ng/
L, p = 0.059) than those without. Natural log-transformed plasma
hs-cTnT levels also correlated significantly with cumulative
anthracycline dose (r = 0.24, p = 0.011). Multivariate analysis
revealed that the significant correlates of plasma hs-cTnT levels
were gender (b=20.63, p,0.001; males having higher hs-cTnT
levels) and cumulative anthracycline dose (b=0.24, p= 0.002)
after adjustment for age at diagnosis, age at study, body mass
index, and history of leukaemic relapse, irradiation involving the
heart, and stem cell transplant.
Genotypes and hs-cTnT Levels
The genotypic and allelic frequencies of NAD(P)H oxidase and
multidrug resistance protein genes in survivors and controls,
excluding the four healthy siblings of survivors, are shown in
table 3. In our ethnic Chinese subjects, none were carrying the
variant alleles of the multidrug resistance proteins MRP1 and
MRP2. Genotypic and allelic frequencies of CYBA and RAC2 were
similar between survivors and controls. The NCF4 GG/AG
genotype was more prevalent than AA genotype in survivors than
controls (p = 0.038).
The genotypic frequencies of CYBA, RAC2, and NCF4 were
similar between group I and group II survivors (Table 2). Stratified
by genetic variants, plasma hs-cTnT levels were significantly
greater in subjects with CT/TT than those with CC genotype at
CYBA rs4673 (Fig. 2). Variants in RAC2 and NCF4 were not
associated with increased hs-cTnT levels.
Plasma hs-cTnT Levels and Cardiac Parameters
Comparisons of echocardiographic parameters between group I
and group II survivors are summarized in Table 4. Compared
with group II survivors, group I survivors had significantly greater
indexed LV mass (p = 0.008), lower systolic (p = 0.041) and early
diastolic (p = 0.045) mitral annular velocities, reduced LV IVA
(p= 0.007) and lower longitudinal systolic strain rate (p = 0.049),
but similar LV ejection fraction (p= 0.19).
Treating hs-cTnT level as a continuous variable, significant
correlations were found between natural log-transformed hs-cTnT
levels and LV mass indexed by body surface area (r = 0.28,
p = 0.006), IVA (r =20.24, p = 0.016), and global longitudinal
systolic strain (r = 0.35, p = 0.001), systolic strain rate (r = 0.26,
p = 0.011), and diastolic strain rate (r =20.31, p = 0.002)
(Figure 3), but not with LV shortening fraction (p = 0.76) and
ejection fraction (p= 0.27).
Discussion
The present study provides the first evidence of increased
circulating hs-cTnT levels in a subgroup of adult survivors of
Figure 1. Levels of high sensitivity cardiac troponin T (hs-cTnT)
in survivors and controls by genders. Distributions of hs-cTnT in
(a) male and (b) female survivors and controls are shown using scatter
plots. Dashed lines represent 95th percentile in controls.
doi:10.1371/journal.pone.0077063.g001
Table 2. Comparisons of demographic factors, clinical
variables, and genotypic frequencies between survivors with
(group I) and without (group II) elevated hs-cTnT levels.
Group I Group II p
(n =19) (n=81)
Demographics
Age (years) 24.763.7 24.064.3 0.52
Sex (M:F) 13:6 44:37 0.31
Weight (kg) 59.8611.6 59.6612.3 0.97
Height (cm) 166.467.7 164.069.0 0.28
Body surface area (m2) 1.760.2 1.660.2 0.66
Clinical variables
ALL:AML 15:4 73:8 0.23
Cumulative doxorubicin
dose (mg/m2)
2886126 201683 ,0.001*
Irradiation involving
the heart (Y:N)
6:13 7:74 0.016*
Relapse (Y:N) 8:11 15:66 0.037*
Stem cell transplant (Y:N) 6:13 9:72 0.036*
Genotypes
CYBA (CC:CT/TT) 14:5 72:9 0.13
RAC2 (TT:TA/AA) 15:4 62:19 1.0
NCF4 (GG/GA:AA) 10.9 47:34 0.80
Abbreviations: AML, acute myeloid leukaemia; ALL, acute lymphoblastic
leukaemia.
*statistically significant.
doi:10.1371/journal.pone.0077063.t002
hs-cTnT in Survivors of Childhood Leukaemias
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e77063
Table 3. Genotypic and allelic frequencies of NAD(P)H oxidase and multidrug resistance protein genes in survivors and control
subjects, and genotypic frequencies reported in Chinese population from National Center for Biotechnology Information (NCBI)
database.
Genotypes Patients Controls
OR
(95% CI) p NCBI
(n=100) (n =38**) database
CYBA
(rs4673)
1.64
(0.63–4.29)a
0.31
CC 86 (86.0%) 30 (78.9%) 86%
CT 13 (13.0%) 8 (21.1%) 14%
TT 1 (1.0%) 0 (0%) 0%
RAC2
(rs13058338)
1.36
(0.59–3.17)b
0.51
TT 77 (77.0%) 27 (71.1%) 86.7%
AT 21 (21.0%) 11 (28.9%) 13.3%
AA 2 (2.0%) 0 (0%) 0%
NCF-4
(rs1883112)
2.27
(1.05–4.90)c
0.038*
GG 15 (15.0%) 2 (5.2%) 9.3%
AG 42 (42.0%) 12 (31.6%) 34.9%
AA 43 (43.0%) 24 (63.2%) 55.6%
MRP1
(rs45511401)
2 2
GG 100 (100%) 38 (100%)
GT 0 (0%) 0 (0%)
TT 0 (0%) 0 (0%)
MRP2
(rs17222723)
2 2
TT 100 (100%) 38 (100%)
TA 0 (0%) 0 (0%)
AA 0 (0%) 0 (0%)
MRP2
(rs8187710)
2 2
GG 100 (100%) 38 (100%) 100%
GA 0 (0%) 0 (0%) 0%
AA 0 (0%) 0 (0%) 0%
Alleles Patients Controls OR
(95% CI)
p
(n=100) (n =38**)
CYBA
(rs4673)
1.45
(0.59–358)
0.47
C 185 68
T 15 8
RAC2
(rs13058338)
1.19
(0.55–2.54)
0.69
T 175 65
A 25 11
NCF-4
(rs1883112)
2.11
(1.13–3.93)
0.02*
G 72 16
A 128 60
MRP1
(rs45511401)
– –
G 200 76
hs-cTnT in Survivors of Childhood Leukaemias
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childhood leukaemia, with a prevalence of 19% in our surviving
cohort studied at a mean of about 15 years after completion of
chemotherapy. Cumulative anthracycline dose received and
history of leukaemic relapse, stem cell transplant, and irradiation
involving the heart are associated with elevated hs-cTnT levels in
univariate and multivariate analyses. Polymorphism of the CYBA
rs4673 is found also to be associated with higher hs-cTnT levels.
Functional implications of increased hs-cTnT level are reflected by
its associations with worse LV systolic and diastolic myocardial
deformation.
Exploration of the changes in circulating cardiac biomarkers in
childhood cancer patients has been limited [18,19]. Elevated
cTnT levels, as assessed using standard assays, after initial
doxorubicin therapy for acute lymphoblastic leukaemia in children
has been shown to associate with LV dilation and wall thinning 9
months later [18] and reduced LV mass 4 years later [19]. In the
first 90 days of treatment, increase in N-terminal pro-brain
natriuretic peptide has also been found to relate to abnormal LV
thickness-to-dimension ratio, which suggests LV remodeling, 4
years later [19]. Other studies have, however, failed to find
correlations between early elevation of cTnT and troponin I with
cardiac dysfunction at a later stage [20,21]. Potential alteration in
hs-cTnT levels late after treatment in long-term survivors has not
been studied previously. To our knowledge, this is the first study to
determine using a highly sensitive assay the circulating cTnT levels
in adult survivors of childhood leukaemia and to interrogate the
clinical determinants and functional implications.
In an adult Caucasian general population, a prevalence of about
37% in men and 13% in women aged younger than 40 years
having detectable hs-cTnT has been reported recently [12]. In the
present study, the prevalence of detectable hs-cTnT was similar
between survivors and controls at about 85–90% in male subjects
and 31–35% in female subjects. Importantly, higher levels of hs-
cTnT in a population-based cohort were associated with LV
structural changes including wall thickening and dilation, LV
systolic dysfunction, and subsequent risk for all-cause mortality
[12]. In 1,072 middle-aged Japanese men without overt cardio-
vascular disease, detectable hs-cTnT levels were found in about
81% [13]. The hs-cTnT levels were further shown to be
significantly associated with cardiovascular risk factors including
age, blood pressure, renal function, current smoking, and LV
hypertrophy, and predicted cardiovascular disease risk [13]. A
prognostic role of hs-cTnT level is increasingly evidenced in
patients with chronic heart failure [22,23], dilated cardiomyopathy
[24], and pulmonary arterial hypertension [25]. Our finding of a
positive correlation between LV mass and hs-cTnT level agrees
with the previously reported findings [13]. Differences in in LV
mass between male and female survivors (70.8615.2 g/m2 vs
61.9618.0 g/m2, p = 0.01) may perhaps also explain the sex
differences in hs-cTnT levels, albeit the reported greater suscep-
tibility to anthracycline cardiotoxicity in female patients [4]. This
further attests to the need for adopting different cut-off values as
discussed below.
Differences in circulating hs-cTnT levels between males and
females are well documented [26]. The 99th percentile limit for
males has been reported to be about 1.7 times as high as the limit
for females [26]. We have therefore derived different cut-off values
based on male and female control subjects. A male cutoff value of
7.91 ng/L corresponds to the highest tertile of hs-cTnT levels in
the recently reported Japanese study, in which patients tertile
cutoffs were respectively #2 ng/L, 3 to 4 ng/L, and $5 ng/L
[13]. This value also corresponds to the 4th highest category of hs-
cTnT levels (6.6 to ,14 ng/L) in the population-based study that
included 3546 adult subjects [12]. These data support our
stratification of survivors into two groups based on the non-
parametric estimate of 95th percentile in healthy controls.
Clinical variables in survivors associated with increased plasma
hs-cTnT levels include cumulative anthracycline dose received
and history of leukaemic relapse, stem cell transplant, and cardiac
irradiation. Cumulative anthracycline dose and cardiac irradiation
are known risk factors for development of late cardiac dysfunction
[4], but none of these were found to correlate with indices of
cardiac function in the present study (data not shown). This
implies perhaps the more sensitive nature of hs-cTnT in the
detection of subtle myocardial damage compared with conven-
tional echocardiographic indices or even the newer parameters of
myocardial deformation [17]. Our findings further support a risk-
stratified long-term screening of cardiac dysfunction according to
cumulative anthracycline dosage received and history of cardiac
irradiation as advocated by the Cardiovascular Disease Task Force
of the Children’s Oncology Group [27].
Table 3. Cont.
Genotypes Patients Controls
OR
(95% CI) p NCBI
(n=100) (n =38**) database
T 0 0
MRP2
(rs17222723)
– –
T 200 76
A 0 0
MRP2
(rs8187710)
– –
G 200 76
A 0 0
*statistically significant.
**4 controls who were siblings of patients were excluded.
aCC vs CT/TT.
bTT vs AT/AA.
cGG/AG vs AA.
doi:10.1371/journal.pone.0077063.t003
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The association between polymorphism of the CYBA rs4673 and
higher hs-cTnT levels is intriguing. The CYBA gene codes for p22-
phox, a subunit that that forms the NAD(P)H oxidase multien-
zyme complex. The T allele at position 242 leads to a missense
mutation His72Tyr. A gene dose-dependent reduction of stimu-
lated NAD(P)H oxidase activity in human neutrophils of T allele
carriers has been reported [28]. On the other hand, increase in
NAD(P)H oxidase activity in cells transferred with CYPA
expression constructs and in neutrophils of human subjects
carrying the T allele has also been described [29]. Notwithstand-
ing the conflicting data on the functional consequences of this
single nucleotide polymorphism, acute anthracycline-induced
cardiotoxicity has been associated with CYBA rs4673 polymor-
phism [5]. Hence, genetic variants in free radical metabolism may
play a role not only in predisposing to acute but also chronic
anthracycline-induced cardiotoxicity. The observed slightly higher
prevalence of NCF4 GG/AG genotype in survivors than in
controls has not been reported previously and needs further
clarification. Nonetheless, this genetic variant is not associated
with hs-cTnT levels. It is worthwhile noting that genotype
distributions of NAD(P)H oxidase and multidrug resistance protein
genes in our ethnic Chinese controls differ from those reported in
Caucasians [5]. On the other hand, genotypic distributions of
CYBA rs4673, RAC2 rs13058338, NCF-4 rs1883112, and MRP2
rs8187710 in our control subjects are similar to those reported in
the Chinese population published in the National Center for
Biotechnology Information (NCBI) database (Table 3).
Although factors associated with increased circulating hs-cTnT
levels in our survivors have been defined, the mechanisms
accounting for the increase are not entirely clear. In long-term
survivors with even preserved LV ejection fraction, we have
previously shown impairment of LV myocardial deformation [17].
Importantly, elevated hs-cTnT levels were associated with indices
of worse systolic and diastolic myocardial deformation. In a mice
model of late-onset doxorubicin-induced cardiotoxicity, juvenile
exposure to anthracyclines has been shown to impair cardiac
progenitor cell function and vascularization and result in greater
susceptibility to exercise and ischaemic stress-induced myocardial
injury in adult mice [30]. Chronic but reversible injury from stress-
induced myocardial strain may hence be a possible culprit leading
to transient changes in cell membrane permeability and leakage of
cTnT in patients after anthracycline therapy [31]. Anthracycline-
induced apoptosis of cardiomyocytes is also recognized [32],
although it remains uncertain whether apoptosis leads to troponin
release [33]. Taken together, although increased hs-cTnT levels
may possibly reflect ongoing cardiomyocyte injury, further studies
are required to unveil the mechanisms of cTnT release late after
completion of anthracycline therapy.
Several limitations to this study deserve comments. First, this is
a case-control study that does not provide data on prognostic
implications of elevated hs-cTnT levels. It would be ideal to
monitor longitudinally the cardiac and functional status of the
survivors through adulthood for determination of the predictive
value of hs-cTnT on development of late cardiomyopathy and
functional impairment in terms of exercise tolerance. Second, the
number of subjects was relatively small and our findings need to be
confirmed in larger scale multi-centre studies. This may possibly
explain the relatively small, albeit statistically significant, differ-
ences between groups I and II patients and the rather weak
association between myocardial deformation parameter and hs-
cTnT levels. In control subjects, we have nonetheless made efforts
to compare the hs-cTnT levels with those reported in the literature
[13,26]. Second, echocardiographic assessment was performed at
rest. A recent study has demonstrated reduced LV contractile
reserve during exercise stress in children previously treated with
anthracycline [34]. Given the reported greater susceptibility to
stress-induced myocardial injury in adult mice with juvenile
anthracycline exposure [30], it would be worthwhile to determine
in long-term survivors the relationship between hs-cTnT levels
Figure 2. Levels of high sensitivity cardiac troponin T (hs-cTnT)
in survivors by NAD(P)H oxidase and multidrug resistance
protein polymorphisms. Scatter plots showing distributions of hs-
cTnT levels in relation to (a) CYBA, (b) RAC2, and (c) NCF4
polymorphisms. Solid lines represent median hs-cTnT levels.
doi:10.1371/journal.pone.0077063.g002
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and LV contractile reserve under stress. Third, we have not
assessed myocardial perfusion in our surviving cohort. Myocardial
perfusion abnormalities have predominantly been found in
patients treated for Hodgkin’s disease and breast cancer [35].
Although none of our survivors have clinical evidence of
myocardial ischaemia, subclinical perfusion abnormalities cannot
completely be excluded. Nonetheless, acute myocardial ischaemia
remains an unlikely explanation for the finding of increased hs-
cTnT levels.
Table 4. Comparisons of echocardiographic findings
between survivors with (group I) and without (group II)
elevated hs-cTnT levels.
Group I Group II p
(n=19) (n=81)
M-mode echocardiographic
indices
Indexed LVEDd (mm) 30.463.8 29.563.6 0.33
Indexed LVESd (mm) 20.663.0 20.562.5 0.83
FS (%) 32.063.1 30.964.0 0.24
Indexed LV mass (g/m2) 76.0623.4 64.6614.3 0.008*
3D echocardiographic induces
LV end-systolic volume
(ml/m2)
34.5611.4 32.368.6 0.37
LV end- diastolic volume
(ml/m2)
71.0618.1 69.9616.4 0.81
LV EF (%) 51.366.6 53.767.3 0.19
Doppler indices
E (cm/s) 86.4615.4 88.4617.5 0.65
A (cm/s) 51.2612.1 48.0612.7 0.32
E/A ratio 1.860.6 2.060.6 0.30
E deceleration time (ms) 171.6638.4 172.9633.9 0.88
s (cm/s) 7.461.8 8.461.8 0.041*
e (cm/s) 211.262.5 212.261.8 0.045*
a (cm/s) 24.461.6 25.361.8 0.052
e/a 2.861.0 2.761.2 0.57
IVA (m/s2) 0.9260.37 1.2660.50 0.007*
Deformation indices
Longitudinal strain (%) 215.262.5 216.263.2 0.19
Longitudinal SRs (/s) 20.8660.14 20.9560.18 0.049*
Longitudinal SRd (/s) 1.2460.33 1.2960.32 0.59
Circumferential strain (%) 214.263.7 214.363.5 0.90
Circumferential SRs (/s) 20.9360.23 20.9560.24 0.74
Circumferential SRd (/s) 1.0860.27 1.1360.41 0.62
Radial strain (%) 32.267.2 33.0611.7 0.79
Radial SRs (/s) 1.7460.39 1.8860.51 0.26
Radial SRd (/s) 21.9660.90 21.8660.61 0.53
Abbreviations: A, peak mitral inflow velocity at late diastole; a, mitral annular
late diastolic myocardial tissue velocity; E, peak mitral inflow velocity at early
diastole; e, mitral annual early diastolic myocardial tissue velocity; EF, ejection
fraction; FS, fractional shortening; IVA, isovolumic acceleration; LV, left
ventricular; LVEDd, left ventricular end diastolic dimension; LVESd, left
ventricular end systolic dimension; SRd, early diastolic strain rate; SRs, systolic
strain rate.
*statistically significant.
doi:10.1371/journal.pone.0077063.t004
Figure 3. Relationships between high sensitivity cardiac
troponin T (hs-cTnT) and indices of left ventricular (LV)
deformation. Correlations between hs-cTnT and LV (a) global
longitudinal systolic strain, (b) systolic strain rate, and (c) diastolic
strain rate are shown. Solid lines represent the best-fit linear regression
and dashed lines represent the 95% confidence interval for each
parameter of the regression line.
doi:10.1371/journal.pone.0077063.g003
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In conclusion, increased hs-cTnT levels occur in a significant
proportion of adult survivors of childhood leukaemias. Higher
levels are associated with larger cumulative anthracycline dose
received and history of leukaemic relapse, stem cell transplant, and
irradiation involving the heart, genetic variants in free radical
metabolism, and worse LV myocardial deformation. Further
longitudinal studies are undoubtedly warranted to confirm our
preliminary findings, to ascertain the prognostic value of elevated
hs-cTnT levels, and to validate the use of hs-cTnT as a biomarker
for screening of anthracycline cardiotoxicity in long-term survivors
of childhood cancers.
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